The Mayo Alzheimer's Disease Patient Registry (ADPR) was initiated in 1986 in response to an RFA from the National Institute on Aging to establish registries for the study of the incidence, prevalence, and risk factors for AIzheimer's Disease (AD) and to refine diagnostic criteria for dementia. Mayo responded by proposing a registry comprised of two sets of projects: One set of projects was designed to use the records-linkage system of the Rochester Epidemiology Project to study incidence, prevalence, and risk factors in the population of Rochester, Minnesota. The other set of projects was designed to establish a prospective, longitudinal cohort of normal and cognitively impaired subjects and to refine the diagnostic criteria for cognitive impairment. This cohort continues to be followed with some subjects having up to15 years of longitudinal data. From this work has come a wealth of research on normal aging, mild cognitive impairment (MCl), and AD, including studies on the normative neuropsychology, neuroimaging, genetics, and neuropathology of this cohort. In this renewal application, the same themes concerning the incidence, prevalence, risk factors, and diagnostic criteria for cognitive impairment and dementia will be pursued; however, there will be a major innovation in methodology. On the advice of our External Advisory Committee, we prepare to use the resources of the Rochester Epidemiology Project to establish a population-based cohort of subjects aged 70-89 years. We plan to recruit a stratified random sample of 2,300 subjects from OImsted County, MN, to study them via telephone contact and direct examination at baseline, and to follow them prospectively by repeated examination annually. Subjects who refuse participation and those who have incomplete follow-up will be studied passively through the records-linkage system. MCl, dementia, and AD will be defined using existing sets of diagnostic criteria. We propose to study the prevalence of MCl and other forms of intermediate cognitive impairment, the incidence of MCI, and to study risk factors or predictors for cognitive impairment. As the field of aging and dementia moves toward the earlier identification of cognitive impairment with the goal of developing prevention strategies, questions regarding the incidence, prevalence, and risk factors for MCl become increasingly important. This population-based cohort will be a valuable resource for additional research on epidemiology, clinical characteristics, neuropsychological features, neuroimaging measures, and neuropathological substrate of prodromal dementia.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AG006786-20
Application #
6935178
Study Section
Special Emphasis Panel (ZAG1-ZIJ-9 (O2))
Program Officer
Anderson, Dallas
Project Start
1986-09-30
Project End
2009-08-31
Budget Start
2005-09-01
Budget End
2006-08-31
Support Year
20
Fiscal Year
2005
Total Cost
$1,246,457
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Wennberg, Alexandra M V; Hagen, Clinton E; Edwards, Kelly et al. (2018) Association of antidiabetic medication use, cognitive decline, and risk of cognitive impairment in older people with type 2 diabetes: Results from the population-based Mayo Clinic Study of Aging. Int J Geriatr Psychiatry 33:1114-1120
Pakhomov, Serguei V S; Eberly, Lynn E; Knopman, David S (2018) Recurrent perseverations on semantic verbal fluency tasks as an early marker of cognitive impairment. J Clin Exp Neuropsychol 40:832-840
Utianski, Rene L; Duffy, Joseph R; Clark, Heather M et al. (2018) Prosodic and phonetic subtypes of primary progressive apraxia of speech. Brain Lang 184:54-65
Jack Jr, Clifford R; Wiste, Heather J; Schwarz, Christopher G et al. (2018) Longitudinal tau PET in ageing and Alzheimer's disease. Brain 141:1517-1528
Townley, Ryan A; Botha, Hugo; Graff-Radford, Jonathan et al. (2018) 18F-FDG PET-CT pattern in idiopathic normal pressure hydrocephalus. Neuroimage Clin 18:897-902
Li, Zeran; Del-Aguila, Jorge L; Dube, Umber et al. (2018) Genetic variants associated with Alzheimer's disease confer different cerebral cortex cell-type population structure. Genome Med 10:43
Krell-Roesch, Janina; Cerhan, Leah P; Machulda, Mary M et al. (2018) Functional Activity and Neuropsychiatric Symptoms in Normal Aging and Mild Cognitive Impairment: The Mayo Clinic Study of Aging. Alzheimer Dis Assoc Disord :
Krell-Roesch, Janina; Feder, Nathanael T; Roberts, Rosebud O et al. (2018) Leisure-Time Physical Activity and the Risk of Incident Dementia: The Mayo Clinic Study of Aging. J Alzheimers Dis 63:149-155
Wennberg, Alexandra M V; Hagen, Clinton E; Machulda, Mary M et al. (2018) The association between peripheral total IGF-1, IGFBP-3, and IGF-1/IGFBP-3 and functional and cognitive outcomes in the Mayo Clinic Study of Aging. Neurobiol Aging 66:68-74
Baker, Darren J; Petersen, Ronald C (2018) Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives. J Clin Invest 128:1208-1216

Showing the most recent 10 out of 591 publications